Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (640)	7/8/1999 3:22:00 PM
From: JDN	Read Replies (1) \| Respond to of 783

Dear Jim: That all sounds good to me, especially if it gets approved in Europe. But why does the stock languish so?? JDN

To: Jim Oravetz who wrote (640)	8/2/1999 12:38:00 PM
From: Jim Oravetz	Respond to of 783

BioChem Pharma Gets E.U. OK For Zeffix Hepatitis B Pdt LAVAL, Quebec -- BioChem Pharma Inc. (BCHE) received approval from the European Commission to market Zeffix, lamivudine, an oral treatment for Hepatitis B, in all 15 countries of the European Union. In a press release Monday, BioChem said it receives royalties from Glaxo Wellcome on sales of Zeffix, as Glaxo has the right to make and sell Zeffix worldwide, except Canada, where the companies sell the product jointly. BioChem said Zeffix reduces liver inflammation and produces, after three years of treatment, seroconversion rates of 65% in patients with active liver disease and 40% in the overall patient group.